13F Holdings
中文EN

TLSI TriSalus Life Sciences, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1826667 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY15.4%
TTM net income YoY33.7%
TTM EPS YoY80.7%
Revenue 3-yr CAGR42.5%
Net income 3-yr CAGR—

Margins

Gross margin86.5%
Operating margin-63.0%
Net margin-56.6%
FCF margin-53.3%
EBITDA margin-61.8%

Returns

ROE—
ROA-55.8%
ROIC (approx.)—
Asset turnover0.99x

Leverage & solvency

Liabilities / assets98.8%
Debt / equity47.60x
Current ratio4.22x
Interest coverage-4.92x

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio-4.0%
Payout ratio—
Capex / revenue0.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$45.15M$29.43M$18.51M$12.40M—
Cost of revenue$6.96M$4.10M$2.60M$2.26M—
Gross profit$38.19M$25.33M$15.91M$10.14M—
R&D expense$14.96M$17.69M$29.84M$21.36M—
SG&A expense$21.46M$17.97M$23.51M$12.48M$3.04M
Operating income-$26.95M-$36.16M-$54.48M-$36.44M-$3.04M
Interest expense$5.54M$3.09M$16,000$1,000—
Pretax income-$39.22M-$30.04M-$59.35M-$47.18M$4.77M
Income tax$7,000$6,000$9,000$9,000$0
Net income-$39.23M-$30.05M-$59.36M-$47.19M$4.77M
EBITDA-$26.32M-$35.42M-$53.79M-$36.04M—
EPS (basic)-1.84-1.31-6.77-161.55—
EPS (diluted)-1.84-1.31-6.77-161.55—
Weighted avg. shares (diluted)37.90M25.33M9.40M309,609—
Balance sheet
Cash & equivalents$20.44M$8.88M$12.13M$9.66M$30.30M
Receivables$6.56M$5.09M$3.55M$1.56M—
Inventory$3.08M$4.05M$2.54M$1.47M—
Current assets$32.24M$20.67M$20.86M$17.21M$525,884
PP&E, net$1.81M$1.67M$2.09M$2.23M—
Intangibles——$0$802,000—
Total assets$35.33M$23.97M$24.60M$22.00M$250.53M
Current liabilities$11.50M$10.23M$14.69M$32.36M$1.60M
Long-term debt$33.05M$22.08M$0——
Total debt$33.05M$22.08M$0——
Total liabilities$69.19M$49.87M$51.66M$34.32M$17.25M
Shareholders' equity-$33.86M-$25.89M-$27.07M-$177.13M-$129.60M
Net debt$12.61M$13.21M-$12.13M——
Shares outstanding50.00M31.28M26.41M347,926—
Cash flow statement
Operating cash flow-$18.01M-$40.84M-$50.58M-$32.31M-$1.74M
Capital expenditure$918,000$345,000$588,000$655,000—
Free cash flow-$18.93M-$41.19M-$51.17M-$32.97M—
Investing cash flow-$838,000-$345,000-$1.59M-$1.79M$60,000
Financing cash flow$30.76M$37.94M$54.63M$13.46M$544,000
Depreciation & amortization$626,000$744,000$684,000$398,000—
Stock-based compensation$9.13M$5.44M$1.40M$368,000—
Share buybacks———$232.37M—

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.